Feasibility and Association of Neurohumoral Blocker Up-titration After Cardiac Resynchronization Therapy

Journal of Cardiac Failure

Volumn 23, Issue 8, 2017, Pages 597-605

  Martens, Pieter ^a,b   Verbrugge, Frederik H ^a   Nijst, Petra ^a,b   Bertrand, Philippe B ^a,b   Dupont, Matthias ^a   Tang, Wilson H ^c   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac resynchronization therapy; neurohumoral blockers; outcome; quality of care

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL OUTCOME; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ANTAGONISTS AND INHIBITORS; DIAGNOSTIC IMAGING; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85016168617     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2017.03.001     Document Type: Article

References (24)

1. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.
2. SOLVD Investigators, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. SOLVD Investigators. N Engl J Med 325 (1991), 293–302.
3. Cohn, J.N., Tognoni, G., A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001), 1667–1675.
4. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999), 9–13.
5. Eichhorn, E.J., Bristow, M.R., The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2 (2001), 20–23.
6. Goldstein, S., Hjalmarson, A., The mortality effect of metoprolol CR/XL in patients with heart failure: results of the MERIT-HF trial. Clin Cardiol 22:Suppl 5 (1999), V30–5.
7. McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Böhm, M., Dickstein, K., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
8. Heywood, J.T., Fonarow, G.C., Yancy, C.W., Albert, N.M., Curtis, A.B., Gheorghiade, M., et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail 3 (2010), 596–605.
9. Komajda, M., Anker, S.D., Cowie, M.R., Filippatos, G.S., Mengelle, B., Ponikowski, P., et al. Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail 18 (2016), 514–522.
10. Packer, M., Poole-Wilson, P.A., Armstrong, P.W., Cleland, J.G., Horowitz, J.D., Massie, B.M., et al., ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999), 2312–2318.
11. Konstam, M.A., Neaton, J.D., Dickstein, K., Drexler, H., Komajda, M., Martinez, F.A., et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374 (2009), 1840–1848.
12. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
13. Mullens, W., Kepa, J., de Vusser, P., Vercammen, J., Rivero-Ayerza, M., Wagner, P., et al. Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy. Am J Cardiol 108 (2011), 409–415.
14. von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
15. Schiller, N.B., Shah, P.M., Crawford, M., DeMaria, A., Devereux, R., Feigenbaum, H., et al., American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2 (1989), 358–367.
16. Driscoll, A., Currey, J., Tonkin, A., Krum, H., Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev(12), 2015 CD009889.
17. Schmidt, S., Hurlimann, D., Starck, C.T., Hindricks, G., Lüscher, T.F., Ruschitzka, F., et al. Treatment with higher dosages of heart failure medication is associated with improved outcome following cardiac resynchronization therapy. Eur Heart J 35 (2014), 1051–1060.
18. Mantziari, L., Guha, K., Khalique, Z., McDonagh, T., Sharma, R., Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis. Am J Cardiol 109 (2012), 1619–1625.
19. Solomon, S.D., Foster, E., Bourgoun, M., Shah, A., Viloria, E., Brown, M.W., et al. Effect of cardiac resynchronization therapy on reverse remodeling and relation to outcome: multicenter automatic defibrillator implantation trial: cardiac resynchronization therapy. Circulation 122 (2010), 985–992.
20. Bristow, M.R., Gilbert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., Hershberger, R.E., et al., MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996), 2807–2816.
21. Fiuzat, M., Neely, M.L., Starr, A.Z., Kraus, W.E., Felker, G.M., Donahue, M., et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail 15 (2013), 258–266.
22. Voigt, A., Shalaby, A., Adelstein, E., Saba, S., Beta-blocker utilization and outcomes in patients receiving cardiac resynchronization therapy. Clin Cardiol 33 (2010), E1–5.
23. Grosu, A., Senni, M., Iacovoni, A., Gori, M., Cantù, F., Bisetti, S., et al. Cardiac Resynchronization in Combination With Beta Blocker Treatment in Advanced Chronic Heart Failure (CARIBE-HF): the results of the CARIBE-HF study. Acta Cardiol 66 (2011), 573–580.
24. Martens, P., Verbrugge, F.H., Nijst, P., Dupont, M., Mullens, W., Mode of death in octogenarians treated with cardiac resynchronization therapy. J Card Fail 22 (2016), 970–977.